Literature DB >> 6442639

Antithrombin III in systemic lupus erythematosus.

M L Boey, S Loizou, C B Colaco, J A Matkin, G R Hughes.   

Abstract

Plasma antithrombin III (AT III) was studied in 39 patients with systemic lupus erythematosus (SLE) and in 12 patients with other connective tissue disorders. AT III was measured immunologically by the Mancini method as well as by functional assay using thrombin and the chromogenic substrate, chromozyn TH (Boehringer). Reduced AT III activity was found in 17 patients; 8 had thrombosis. In 6 patients low AT III correlated with disease exacerbations and 2 had systemic vasculitis. No significant correlation could be demonstrated between low AT III levels and thromboembolic disease. A marked variation of functional AT III activity was observed in 30 patients in whom the presence of the lupus anticoagulant was demonstrated. The significance of this association is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6442639

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

Review 1.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

2.  Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal.

Authors:  R A Asherson; J K Chan; E N Harris; A E Gharavi; G R Hughes
Journal:  Ann Rheum Dis       Date:  1985-12       Impact factor: 19.103

3.  Risk factors for thrombosis in lupus patients.

Authors:  P Hasselaar; R H Derksen; L Blokzijl; M Hessing; H K Nieuwenhuis; B N Bouma; P G De Groot
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

4.  Characterization and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS).

Authors:  M B Hill; J L Phipps; R G Malia; M Greaves; P Hughes
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.